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A BASIC premise of this study is that it is desirable to treat patients with Gram-negative 
bacteremia with an appropriate antibiotic in the early stages of the infection. This 
does not mean that other therapeutic measures can be ignored; indeed, we wish to 
emphasize the importance of incision and drainage of abscesses, relief of urinary 
obstruction, removal of infected foreign bodies, monitoring of central venous pressure, 
restoration of intravascular volume, and use of appropriate vasoactive amines. In 
most cases even the best antibiotic therapy will not succeed unless attention is given 
to these other measures. The beneficial effects of antibiotics are often slow to be 
noticed; they cannot be evidenced until many infecting bacteria are inhibited or 
killed, and reparative processes begin. We emphasize these other aspects of the treat- 
ment of infection because we will devote the rest of this paper to a discussion of a 
potent and potentially dangerous antibiotic regimen, especially when used by those 
unfamiliar with its properties. Nephrotoxicity and ototoxicity are the major problems. 
The vast majority of patients with infections do not require this regimen; it should 
be used only for serious infections, even then infrequently and selectively; and only 
by those who have become familiar with the proper use of these antibiotics. The 
regimen does not negate the need for appropriate cultures to document the nature 
of the infection. 
We observed 50 patients at The Johns Hopkins Hospital treated with a regimen 
consisting of cephalothin, kanamycin, and colistin (33 patients were treated with 
intravenous polymyxin B sulfate instead of intramuscular colistin methanesulfonate). 
For the rest of this paper we shall refer to this regimen as CKC. We will tell why 
this regimen became popular, what its efficacy seemed to be, and what its toxicity 
has been. 
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METHODS 
When we noted that CKC was being used frequently at The Johns Hopkins Hospital, 
we decided to locate and follow as many of the adult patients being treated withit as 
possible. Case flnding was facilitated by notification from the hospital pharmacy 
when all three antibiotics were ordered for a patient, by follow-up of patients with 
positive blood cultures, and by regular inquiries on the medical wards. Almost all 
of the patients were not under our direct care, and the study is thus a retrospective 
analysis of the regimen as used by others. 
In general, the physicians using CKC selected it because they believed the patients 
had bacteremia caused by Gram-negative bacilli. Almost invariably, it was used 
before results of cultures, sensitivity tests, and other diagnostic measures were available. 
The regimen was popular because the preliminary results of a study of antibiotic 
combinations in our laboratory showed that CKC had very broad antibacterial 
activity. 
Antibiotics were used parenterally, usually in the following dosages: cephalothin, 
6-12 g/day; kanamycin, 1.0-1.5 g/day; colistimethate sodium, 5 mg/kg/day. Three 
patients received polymyxin B sulfate intravenously (instead of colistin) in doses of 
2.5 mg/kg/day, but no more than 200 mg/day. Doses of kanamycin and colistin 
were reduced in patients with impaired renal function, but not according to any 
uniform guidelines. 
Organisms were identified and their susceptibility to antibiotics was determined 
by the low concentration disc method in the routine clinical microbiology laboratory 
of the hospital by standard methods [l]. We also obtained many of these organisms, 
and determined their bacteriostatic and bactericidal susceptibility by serial broth 
dilution in tubes by methods detailed elsewhere [2]. A sample of laboratory stock 
strains of 60 Gram-negative bacilli (12 each of Esch. coli, Klebsiella-Enterobacter, 
Pseudomonas, Proteus mirabilis, and indol-positive Proteus species) was also studied 
in our laboratory by broth methods. Susceptibility to single antibiotics as well as to 
a mixture containing cephalothin 10 pg/ml, kanamycin sulfate 20 pg/ml, and colistin 
sulfate 5 pg/ml was determined on this sample, and the observed results with the 
mixture was compared with the expected results predicted from susceptibility tests 
with single antibiotics. 
RESULTS 
Ninety-four per cent of Gram-negative bacilli studied in our laboratory were 
inhibited at concentrations attainable in serum [3] by one or more antibiotics in the 
combination. In addition, pneumococci, Group A l3 hemolytic streptococci, and 
coagulase-positive staphylococci were susceptible. Cephalothin and kanamycin were 
synergistic towards enterococci [3]. Thus, these organisms would probably be suscept- 
ible. Many other relatively rare coliforms would also be susceptible to one or more 
of them. Fungi are probably resistant, but this has not been examined. All three 
antibiotics in the combinations are bactericidal. It was the most frequently inhibitory 
antibiotic combination we studied. Thus, it was used in the Johns Hopkins Hospital 
primarily in serious, life-threatening infections where the nature of the etiologic 
agent could not readily be deduced by consideration of the site of the infection, the 
Gram-stain of exudate, the physical examination, and by bacteriologic results already 
available. It was intended as an emergency or stop-gap treatment, and one that was 
to be modified as soon as clinical and bacteriological results permitted. 
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Susceptibility of the organisms 
On the basis of the behavior of antibiotics tested singly, we predicted that 79 per 
cent of the laboratory strains we selected for special study would be inhibited by the 
mixture of CKC. The observed frequency of inhibition with the mixture was 87 per 
cent. Bactericidal action was predicted with 57 per cent of the strains; 77 per cent 
killing was actually observed. With none of the species was there evidence of antagon- 
ism in the mixtures. 
The susceptibility data obtained with organisms isolated from the Mty patients 
treated with the combination in this study were also encouraging. These organisms 
are listed in Table 1. All bacteria isolated from these patients were susceptible to one 
or more of these three antibiotics. The results with 39 Gram-negative bacilli studied 
in our laboratory are summarized in Table 2. All of the organisms were sensitive 
to both kanamycin and colistin. A polymyxin is important in the combination because 
it is the only available drug with good activity towards Pseudomonas strains. We 
considered colistin to be the same as polymyxin E. 
An infection was ultimately well-documented in 88 per cent of the 50 patients; 
and in 95 per cent of the documented infections a Gram-negative bacillus was impli- 
TABLE 1. ORGANISMS ISOLATED FROM PATIENTS WITH DOCUMENTED INFECTIONS 
Organisms Number of isolations Percentage of total 
E. coli 15 27.8 
Klebsiella-aerobacter 11 20.4 
Paracolon 6 11.1 
Pseudomonar 5 9.3 
Proteus mirabilis 4 7.4 
Anaerobic streptococci 3 5.6 
Pneumococci 2 3.7 
Staphylococcus aureus 2 3.7 
Proteus vulgaris 2 3.7 
Streptococcus fecaIis 1 1.9 
Staphylococcus albus 1 1.9 
Proteus rettgeri 1 1.9 
Hemophilus influenzae 1 1.9 
Total 54 
TABLE 2. SUSCEP~LBLLIT~ OF THIRTY-NINE GRAM-NEGATNE BACILLI 
ISOLATED FROM PATIENTS IN THE STUDY 
Antibiotics* Number organisms sensitive Percentage organisms sensitive 
Kanamycin, cephalothin and colistin 39 100.0 
Kanamycin and colistin 39 100.0 
Cephalothin and colistin 36 92.4 
Kanamycin and cephalothin 33 84.8 
Kanamycin 31 79.5 
Colistin 31 79.5 
Cephalothin 26 66.8 
*Cephalothin 10 pgfm!. 
Kanamycin 20 Kg/ml. 
Colistin 5 Pg/ml. 
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cated. The infections are listed in Table 3. Bacteremia was documented in 14 of the 
50 patients, or 28 per cent of the total; all of these organisms were Gram-negative 
bacilli (Table 4). Two patients had 2 episodes of bacteremia. Most of the patients 
with bacteremia had serious underlying diseases, and thus were relatively poor-risk 
patients. Their clinical details are presented in Table 5. A urinary tract infection was 
the apparent source of the bacteremia in most of the patients, and the infection was 
often related to instrumentation of the genitourinary tract or Foley catherization. 
In all but one of the patients with bacteremia, the infection was hospital-acquired. 
The therapeutic results in the patients with bacteremia are shown in Table 6. 
Twenty-one (42 per cent) of the patients in this study died. Four (25 per cent) of 
the 16 episodes of bacteremia ended fatally. Oliguria with hypotension was an ominous 
sign in bacteremia, since 37.5 per cent of the patients with these signs died. The 
difference in fatality rates of bacteremic and non-bacteremic cases was not statistically 
significant. 
It was especially difficult to estimate the efficacy of the regimen when the patients 
without bacteremia were considered. All we can say about the efficacy of the com- 
bination in these patients is that there were no obvious bacteriologic failures and that 
the rapidity of response was about what one might have expected for an appropriate 
antibiotic. 
TABLET. INFEC~ONS DIAONOSEDINHITY PATIENTS RJXEIVINOCEPHALOTHP~, 
KANAhlYCXN,ANDCOLISTIN* 
Type of infection Number with bacteremia 
Urinary tract infection 9 
Pneumonia 1 
Bacteremia, source unknown 4 
Wound infection 0 
Peritonitis 0 
Soft tissue abscess 0 
Cholangitis I 
Phlebitis, catheter site 1 
Pyometra 0 
Cellulitis 0 
Infection not proven 0 






















*Some patients had more than 1 infection. 
55. 
TABLE 4. OROANISMSISOLATEDFROMTHEBLOODOPPATIENTS~THBACTEREMIA* 
Organism Number of patients 
Klebsiella-Aerobacter 4 
E. coli 4 
Paracolon 3 
Pseudomonas 3 
Proteus mirabilis 1 
E. coli and Pseudomonas 1 
Total 16 
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TABLE 6. OUTCOME IN PATIENIX WITH GRAM-NEGATTVE BACTEREMIA TREATED WITH THE 
COMBINATION 
Clinical condition 







No hypotension 3 0 0.0 
Hypotension (total) 13 4 30.7 
Hypotension without oliguria 5 1 20.0 
Severe hypotension with oliguria (shock) 8 3 37.5 
Total episodes 16 4 25.0 
Total patients 14 4 28.6 
Toxicity 
No hematologic toxicity was documented. A possible superinfection was noted 
in 2 patients; 1 developed mild cutaneous moniliasis. The other (Table 5) 
developed Klebsiella bacteremia and died after recovering from Esch. coli bacteremia. 
Gastrointestinal side effects were infrequent. Pain at the sites of injection or phlebitis 
at sites of intravenous administration were common. One patient developed fever 
probably attributable to drugs. No other hypersensitivity reactions were seen despite 
the fact that 5 patients had a history of drug allergy in the past, and 3 of them were 
probably allergic to penicillin. 
Paresthesias (a well-recognized side effect of the use of colistin) occurred, but 
were not troublesome. Three patients underwent general anesthesia while receiving 
the combination, and none of them developed apnea. None of the patients developed 
gross ototoxicity or ataxia. 
We summarized effects of therapy on serum urea nitrogen in Table 7. It must be 
emphasized that 68 per cent of the patients in this study were hypotensive, and that 
86 per cent of those with bacteremia were hypotensive. Most of the patients received 
the combination for no more than 3 days, and 37 per cent of the patients receiving 
therapy for only 3 days developed elevations of the serum urea nitrogen. Elevation 
of the urea nitrogen (SUN) was more frequent when therapy was continued for more 
TABLET. EFFECTOFTREATMENTWITHCEPHALQTHIN,KANAMYCIN, 




Pre-treatment Pre-treatment Total number 
SUN normal SUN abnormal and percentage 
(No. patients) (No. patients) of grand total 
Decrease 0 14 14 (30) 
No change 11 3 14 (30) 
Transient increase 4+ 3* 7* (15) 
Progressive increase in patients who died 4 7 11 (24) 
Permanent increase in survivors 0 0 0 ( 0) 
Total 19 27 46t 
*All of these patients developed hypotension during this illness except for 1 who had bilateral 
obstruction. 
tFour patients excluded because of inadequate data. 














10, 11 0 
12 3 
than three days (it was noted in 57 per cent of these patients), but the difference 
between these groups was not significant (x2= 1.9, p >O. 1). 
Nineteen patients had apparently normal renal function at the time the combination 
was begun. Four of them had transient elevations of the urea nitrogen; three had 
hypotension during their infection and the other had bilateral ureteral obstruction. 
Thirty-four patients developed hypotension during treatment; in 17 with a brief 
hypotensive episode the SUN decreased or remained stable during therapy, in 6 it 
became transiently elevated, and it rose progressively in eleven patients who died. 
Twenty-seven, or more than 50 per cent of the patients, had impaired renal function 
at the time CKC was begun, and 24 (89 per cent) of these had hypotension as well. 
Renal function improved, as measured by the urea nitrogen, in 52 per cent of these 
patients after treatment (Table 7). In 10 (42 per cent) of 24 patients with hypotension 
as well as impaired renal function at the onset of the infection, the urea nitrogen 
rose still further during therapy. Seven of these 10 were patients who died of their 
basic disease. In the other three, the urea nitrogen was only transiently elevated and 
ultimately returned to the level observed prior to therapy. 
Patients who survived the infection for which they were given the combination 
never demonstrated persistent evidence that their renal function had been impaired 
by the antibiotics, as measured by the SUN or serum creatinine*. Seven patients had 
transient elevations of the SUN during therapy. Most had severe underlying disease 
as well as hypotension and decreased renal perfusion. 
Eleven patients treated with the combination had a rising SUN at the time of 
death. All of the patients had severe underlying disease, with multiple reasons for 
developing impaired renal function. Autopsies were performed on 6 of these patients. 
These showed tubular necrosis in 5 of the 6 patients. The problem of identifying the 
cause of these histologic findings has been discussed in greater detail in an earlier 
study of colistin (5). 
The duration of treatment with CKC in our 50 patients is shown in Table 8. The 
median and mean duration of therapy with these antibiotics were 3 and 4 
days respectively. Ten of the 50 patients (20 per cent) received all 3 antibiotics for 
*The upper limit of normal for SUN and creatinine was 19 and 1.2 mg./lOO ml, respectively. 
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No nephrotoxic antibiotics (susceptibility of 
organism not always proven) 
No nephrotoxic antibiotics (regimen appropriate) 
CoIistin (appropriate) 
Cephalothii, kanamycin, and colistin (appropriate) 
12 23 52.1 
4 14 28.6 
9 20 45.0 
6 14 42.9 
6 or more days, and 3 patients were treated for a total of 12 days. The SUN in 8 
of the 10 patients who were treated with the combination for more than 6 days 
remained normal or declined to normal during therapy. One of the remaining 2 
patients treated for more than 6 days developed an elevation of the SUN from 14 
to 63 mg/lOO ml during a possible episode of bacteremic shock. He subsequently 
died from a cardiac arrhythmia. The serum urea nitrogen of the other patient rose to 
114 mg/lOO ml while he was being treated for severe necrotizing pancreatitis and 
shock. He recovered, and his SUN subsequently returned to normal. In both of these 
patients, other causes of azotemia in addition to nephrotoxic drugs were present. 
We retrospectively reviewed the hospital records of 43 other adult patients 
with documented Gram-negative bacteremia. The results are presented in Table 9. 
Pencillin G, ampicillin, tetracycline, chloramphenicol, and streptomycin were assumed 
not to be nephrotoxic for this analysis. It was apparent that nephrotoxicity was 
frequent even when relatively safe antimicrobials were given (28.6 per cent), and 
CKC did not seem to be worse than colistin alone. 
DISCUSSION 
Our therapeutic results compare favorably with those reported in the literature 
[4], but we do not wish to make any claim that the combination of CKC is more 
efficacious than a variety of other popular regimens. The number of cases with 
bacteremia we have seen thus far is small. Furthermore, we believe that a number of 
other measures now in common use in treatment of patients with Gram-negative 
infection may contribute to better survival rates. These include the monitoring of 
central venous pressure, more intelligent replacement of intravascular fluid deficits, 
a more rational use of vasoactive amines and the use of pharmacological doses of 
adrenal steroids. We believe it is bad to treat patients with sepsis with adrenal steroids 
unless they are receiving appropriate antibiotics, and this is one of the reasons we 
have been encouraged to pursue our studies with CKC. 
In severe infections with bacteremia, our data suggest that the combination of 
cephalothin, kanamycin, and colistin can be used with safety, and that it assures 
excellent antibacterial activity against a wide range of organisms early in the course 
of infections. Once the nature of the infection is established, the regimen frequently 
can and should be modified so that less toxic antimicrobial drugs are used. That we 
observed no serious nephrotoxicity definitely attributable to the antibiotics justifies 
no complacency, since two of these antibiotics have well recognized nephrotoxic 
potentials. Our data show that the risk of serious nephrotoxic reactions is not pro- 
hibitive in these patients, but we believe such reactions will undoubtedly occur from 
time to time. 
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While most of these patients were treated with colistin methanesulfonate, this 
antibiotic is closely related to polymyxin B, and it is likely the results are equally 
applicable to the latter antibiotic used in appropriate and recommended amounts. 
SUMMARY 
Fifty hospitalized adults suspected of having Gram-negative bacteremia were 
treated with cephalothin, kanamycin, and a polymyxin. Sixteen episodes of bacteremia 
in 14 patients were documented. Urinary tract infections and pneumonia were most 
frequent. All bacteria isolated from these patients were susceptible to 1 or more of 
the antibiotics used. Four of 16 episodes of bacteremia ended fatally. Three of 8 
patients with bacteremia and shock died. 
Most of the patients developed hypotension or shock during infection. Fifty-nine 
per cent had evidence of impaired renal function before treatment, but only 40 per 
cent of all patients manifested deterioration of renal function during therapy. Acute 
tubular necrosis was frequently found in those with bacteremia who died. No survivors 
showed evidence of permanent impairment of renal function. We believe this com- 
bination of antibiotics is beneficial, and can be used safely by those familiar with its 
hazards. 
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